Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2011-02-15
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 399
- Registration Number
- NCT00499018
- Locations
- 🇮🇹
Istituto Vito Fazzi, Lecce, Italy
🇮🇹Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Salerno, Italy
🇮🇹Az. Osp. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2009-05-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 374
- Registration Number
- NCT00494897
- Locations
- 🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital general de Castellón, Castello, Castellón, Spain
🇪🇸Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients
- Conditions
- Interventions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 59
- Registration Number
- NCT00494780
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer
- Conditions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2007-06-26
- Target Recruit Count
- 24
- Registration Number
- NCT00491946
- Locations
- 🇺🇸
Abramson Research Center, Philadelphia, Pennsylvania, United States
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 107
- Registration Number
- NCT00477412
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
ALL Adult Consortium Trial: Adult ALL Trial
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 112
- Registration Number
- NCT00476190
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Boston, Boston, Massachusetts, United States
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
- Conditions
- Interventions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 101
- Registration Number
- NCT00451178
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Crosse, Wisconsin, United States
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)
- Conditions
- Interventions
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 57
- Registration Number
- NCT00450385
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸University of Rochester Medical Center - Wilmot Cancer Institute, Rochester, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 22
- Registration Number
- NCT00450801
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2014-03-21
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 30
- Registration Number
- NCT00441168
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.